Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

(2011) Ralf A. Linker et al.   BRAIN

Differential regulation of the proapoptotic multidomain protein Bak by p53 and p73 at the promoter level

(2011) V Graupner et al.   CELL DEATH AND DIFFERENTIATION

Fumarate Esters as Angiogenesis Inhibitors: Key to Action in Psoriasis?

(2011) Jack L. Arbiser   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Targeting glutathione by dimethylfumarate protects against experimental malaria by enhancing erythrocyte cell membrane scrambling

(2010) Mehrdad Ghashghaeinia et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis

(2010) Robert C Axtell et al.   NATURE MEDICINE

Direct crosstalk between mast cell-TNF and TNFR1-expressing endothelia mediates local tissue inflammation

(2009) M. Kneilling et al.   BLOOD

Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment

(2009) Marcin Kortylewski et al.   CANCER CELL

Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair

(2009) Oliver Rothfuss et al.   HUMAN MOLECULAR GENETICS

AP-1 Activated by Toll-like Receptors Regulates Expression of IL-23 p19

(2009) Weicheng Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Myeloid heme oxygenase–1 regulates innate immunity and autoimmunity by modulating IFN-β production

(2009) Sotiria Tzima et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways

(2009) Rajan P Nair et al.   NATURE GENETICS

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ethyl pyruvate has an anti-inflammatory effect by inhibiting ROS-dependent STAT signaling in activated microglia

(2008) Hong Sook Kim et al.   FREE RADICAL BIOLOGY AND MEDICINE

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

(2008) Benjamin M Segal et al.   LANCET NEUROLOGY